What is SFC Fluidics?
SFC Fluidics, Inc. is at the forefront of developing next-generation devices designed to revolutionize diabetes care. Their flagship innovation, the proprietary Panda Insulin Delivery System, directly addresses the critical healthcare challenge posed by diabetes, a condition that accounts for a substantial portion of global healthcare expenditures. By focusing on enhancing clinical outcomes and reducing treatment costs, SFC Fluidics aims to significantly improve patient lives. As part of the VIC Technology Venture Development ecosystem, the company is strategically positioned to broaden its technological applications beyond diabetes to other disease states, leveraging its expertise in fluidics and device engineering.
How much funding has SFC Fluidics raised?
SFC Fluidics has raised a total of $3.6M across 5 funding rounds:
Private Equity
$1M
Series B
$2M
Unspecified
$175K
Debt
$144K
Private Equity
$250K
Private Equity (2013): $1M, investors not publicly disclosed
Series B (2014): $2M, investors not publicly disclosed
Unspecified (2015): $175K supported by National Institutes of Health
Debt (2021): $144K featuring PPP
Private Equity (2025): $250K, investors not publicly disclosed
Key Investors in SFC Fluidics
National Institutes of Health
The National Institutes of Health (NIH) is a primary agency of the U.S. Department of Health and Human Services, dedicated to biomedical and health-related research, providing crucial backing for scientific advancements.
What's next for SFC Fluidics?
With the recent influx of major strategic investment, SFC Fluidics is expected to accelerate its product development pipeline and expand its market reach. The company's focus on improving diabetes care through innovative technology, coupled with its potential to address other disease states, positions it for significant growth. Future endeavors will likely involve scaling manufacturing capabilities, pursuing regulatory approvals for new applications, and forging strategic partnerships to enhance distribution and adoption of its advanced medical devices. The enterprise-level funding provides the necessary capital to drive these initiatives forward and solidify its position in the competitive medtech landscape.
See full SFC Fluidics company page
